中国医学科学院学报

高级检索
中国医学科学院学报

中国医学科学院学报 ›› 2013, Vol. 35 ›› Issue (1): 116-120.doi: 10.3881/j.issn.1000-503X.2013.01.022

• 论著 • 上一篇    下一篇

利妥昔单抗治疗难治及复发性血栓性血小板减少性紫癜的疗效和安全性

崔静,朱铁楠,邹农,陈苗,赵永强   

  1. 中国医学科学院 北京协和医学院 北京协和医院血液科,北京 100730
  • 收稿日期:2012-07-17 出版日期:2013-03-07 发布日期:2013-03-07
  • 通讯作者: 朱铁楠 电话:010-69158293, 电子邮件:tienanzhu@gmail.com E-mail:tienanzhu@gmail.com

Efficacy and Safety of Rituximab Therapy for Refractory/relapsingThrombotic Thrombocytopenic Purpura

CUI Jing, ZHU Tie-nan, ZOU Nong, CHEN Miao, ZHAO Yong-qiang   

  1. Department of Hematology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China
  • Received:2012-07-17 Online:2013-03-07 Published:2013-03-07

摘要: 目的 评价利妥昔单抗治疗难治及复发性血栓性血小板减少性紫癜(TTP)的疗效及安全性。方法 采用利妥昔单抗,每周375 mg/m2,连续2~4周治疗3例难治及复发性TTP,并进行每3个月1次的随访观察。结果 3例患者均获得完全缓解,利妥昔单抗治疗后血小板中位恢复时间是在首次输注利妥昔单抗的第7天(4~12d)。中位随访12个月(9~18个月),3例患者疾病均无复发,治疗期间和随访期内均无不良反应。结论 利妥昔单抗可有效治疗难治性或慢性复发性TTP,且耐受性良好。   

关键词: 血栓性血小板减少性紫癜, 治疗, 利妥昔单抗

Abstract: Objective To evaluate the efficacy and safety of rituximab in treating patients with refractory and/or relapsing thrombotic thrombocytopenic purpura (TTP). Methods Totally three patients received rituximab as salvage therapy in our hospital. Rituximab was administered at a weekly dose of 375 mg/m2 for 2 or 4 consecutive weeks. After clinical remission, patients were followed up every 3 months. Results All three patients achieved complete remission. The median time to platelet count recovery was 7 days (4-12 days) after the first rituximab infusion. During the follow-up (median: 12 months; range: 9-18 months), no patients experienced relapse. No side effect was noted during treatment and follow-up period. Conclusion Therapy with rituximab is effective and well tolerated for patients with refractory or relapsing TTP.

Key words: thrombotic thrombocytopenic purpura, treatment, rituximab

中图分类号: